Topical antibacterial agents for wound care: A primer

Dermatologic Surgery

Volumn 29, Issue 6, 2003, Pages 620-626

  Spann, Candace Thornton ^a   Tutrone, William D ^a   Weinberg, Jeffrey M ^a   Scheinfeld, Noah ^a   Ross, Bonnie ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACITRACIN; BACITRACIN ZINC; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LINCOSAMIDE; MACROLIDE; NEOMYCIN; NEOSPORIN; OFLOXACIN; OXACILLIN; PEXIGANAN ACETATE; POLYMYXIN; POLYMYXIN B; POLYSPORIN; PROTEGRIN; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFADIAZINE SILVER;

ACNE; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; BURN INFECTION; CONCENTRATION RESPONSE; CONTACT DERMATITIS; CREAM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG SENSITIZATION; DRUG TOLERABILITY; ERADICATION THERAPY; FURUNCULOSIS; HUMAN; IMPETIGO; KERNICTERUS; LEUKOPENIA; NEUTROPENIA; PRIORITY JOURNAL; PSEUDOMONAS FLUORESCENS; RECURRENT DISEASE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; WOUND CARE; WOUND INFECTION;

ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; HUMANS; SKIN CARE; SKIN DISEASES, BACTERIAL; WOUND HEALING;

EID: 0038115689     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4725.2003.29143.x     Document Type: Article

References (33)

1. Rhody C. Bacterial infections of the skin. Prim Care 2000;27:459-73.
2. Kaye ET. Topical antibacterial agents. Infect Dis Clin North Am 2000;14:321-9.
3. Gisby J, Bryant J. Efficacy of new cream formulation of mupirocin: comparison with oral and topical agents in experimental skin infections. Antimicrob Agents Chemother 2000;44:255-60.
4. Hanifin JM, Tofte SJ. Update on therapy of atopic dermatitis. J Allergy Clin Immunol 1999;104:S123-5.
5. Scully BE, Briones F, Gu JW, et al. Mupirocin treatment of nasal staphylococcal colonization. Arch Intern Med 1992;152:353-6.
6. Raz R, Miron D, Colodner R, et al. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med 1996;156:1109-12.
7. Harbarth S, Dharan S, Liassine N, et al. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Stapylococcus aureus. Antimicrob Agents Chemother 1999;43:1412-6.
8. Physicians Desk Reference, 55th ed. New Jersey: Medical Economics Company, 2001.
9. Larson EL. APIC guideline for hand washing and hand antisepsis in healthcare settings. Am J Infect Control 1995;23:251-69.
10. Henkel T, Finlay J. Emergence of resistance during mupirocin treatment: is it a problem in clinical practice? J Chemother 1999;11:331-7.
11. Bernstein SC, Roenigk RK. Surgical pearl: erythromycin ointment for topical antibiotic wound care. J Am Acad Dermatol 1995;32:659-60.
12. Saryan JA, Dammin TC, Bouras AE. Anaphylaxis to topical bacitracin zinc ointment. Am J Emerg Med 1998;16:512-3.
13. Vale MA, Connolly A, Epstein AM, et al. Bacitracin-induced anaphylaxis. Arch Dermatol 1978;114:800.
14. Schecter JF, Wilkinson RD, Del Carpio J. Anaphylaxis following the use of bacitracin ointment. Arch Dermatol 1984;120:909-11.
15. Comaish JS, Cunliffe WJ. Absorption of drugs from various ulcers: a cause of anaphylaxis. Br J Clin Pract 1967;21:97-8.
16. Selcow JE. Life-threatening anaphylaxis following topical administration of bacitracin ointment. Proc N E Soc Allergy 1982;3:255-7.
17. Smack DP, Harrington AC, Dunn C, et al. Infection and allergy incidence in ambulatory surgery patients using a white petrolatum vs bacitracin ointment: a randomized controlled trial. J Am Acad Dermatol 1996;276:972-7.
18. Monafo WW, West MA. Current treatment recommendations for topical burn therapy. Drugs 1990;40:364-73.
19. Ward RS, Saffle JR. Topical agents in burn and wound care. Phys Ther 1995;75:526-38.
20. Sinha R, Agarwal RK, Agarwal M. Povidone iodine plus neosporin in superficial burns: a continuing study. Burns 1997;23:626-8.
21. de Gracia CG. An open study comparing topical silver sulfadiazine and topical silver sulfadiazine-cerium nitrate in the treatment of moderate and severe burns. Burns 2001;27:67-74.
22. Steinstraesser L, Klein RD, Aminlari A, et al. Protegrin-1 enhances bacterial killing in thermally injured skin. Crit Care Med 2001;29:1431-7.
23. Frohm M, Agerberth B, Ahangari G, et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 1997;272:15258-63.
24. Ganz T, Weiss J. Antimicrobial peptides of phagocytes and epithelia. Semin Hematol 1997;34:343-54.
25. Huttner KM, Lambeth MR, Burkin HR, et al. Localization and genomic organization of sheep antimicrobial peptide genes. Gene 1998;205:85-91.
26. Travis SM, Anderson NN, Forsyth WR, et al. Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun 2000;68:2748-55.
27. Steinberg DA, Hurst MA, Fujii CA, et al. Protegrin-1: a broad spectrum, rapidly microbicidal peptide with in vivo activity. Antimicrob Agents Chemother 1997;41:1738-42.
28. Heller WT, Waring AJ, Lehrer RI, et al. Membrane thinning effect of the beta-sheet antimicrobial protegrin. Biochemistry 2000;39:139-45.
29. Mangioni ME, Aumelas A, Charnet P, et al. Change in membrane permeability induced by protegrin 1: implication of disulphide bridges for pore formation. FEBS Lett 1996;383:93-8.
30. Harwig SS, Waring A, Yang HJ, et al. Intramolecular disulfide bonds enhance the antimicrobial and lytic activities of protegrins at physiological sodium chloride concentrations. Eur J Biochem 1996;240:352-7.
31. Fortney K, Totten PA, Lehrer RI, et al. Haemophilus ducreyi is susceptible to protegrin. Antimicrob Agents Chemother 1998;42:2690-3.
32. Ge Y, MacDonald DL, Holroyd KJ, et al. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother 1999;43:782-8.
33. Ge Y, MacDonald D, Henry MM, et al. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn Microbiol Infect Dis 1999;35:45-53.